Theriva Total Stockholder Equity from 2010 to 2024
| TOVX Stock | USD 1.18 0.01 0.84% |
Total Stockholder Equity | First Reported 1993-03-31 | Previous Quarter 27.6 M | Current Value 24.6 M | Quarterly Volatility 19.5 M |
Check Theriva Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Theriva Biologics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 101.5 K, Total Revenue of 0.0 or Other Operating Expenses of 13.9 M, as well as many indicators such as Price To Sales Ratio of 241, Dividend Yield of 0.0 or PTB Ratio of 0.17. Theriva financial statements analysis is a perfect complement when working with Theriva Biologics Valuation or Volatility modules.
Theriva | Total Stockholder Equity |
Latest Theriva Biologics' Total Stockholder Equity Growth Pattern
Below is the plot of the Total Stockholder Equity of Theriva Biologics over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Theriva Biologics' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Theriva Biologics' overall financial position and show how it may be relating to other accounts over time.
| Total Stockholder Equity | 10 Years Trend |
|
Total Stockholder Equity |
| Timeline |
Theriva Total Stockholder Equity Regression Statistics
| Arithmetic Mean | 21,205,590 | |
| Coefficient Of Variation | 95.79 | |
| Mean Deviation | 16,624,920 | |
| Median | 14,365,000 | |
| Standard Deviation | 20,313,576 | |
| Sample Variance | 412.6T | |
| Range | 66.9M | |
| R-Value | 0.71 | |
| Mean Square Error | 221T | |
| R-Squared | 0.50 | |
| Significance | 0 | |
| Slope | 3,220,232 | |
| Total Sum of Squares | 5777T |
Theriva Total Stockholder Equity History
About Theriva Biologics Financial Statements
Theriva Biologics investors use historical fundamental indicators, such as Theriva Biologics' Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Theriva Biologics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Stockholder Equity | 39.7 M | 41.7 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Theriva Stock Analysis
When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.